Cytological Biomarkers

Cytology have been act as a main tools utilised in the diagnosis of cancer. These techniques have evolved from an era of diagnosis based on haematoxylin and eosin (H&E) stained slides  to the current regular evaluation of tumours by immunocytochemistry (IHC) to confirm tumour histogenesis and subtype. In breast cancer, this means the routine IHC evaluation of hormone receptors (oestrogen and progesterone receptors) as well as evaluation of HER2 expression  and Ki67 (a marker of tumour proliferation). These factors strongly influence prognosis and the selection of anti-cancer treatments.

 

  • cytological carcinoma
  • Cytopathology marker

Related Conference of Cytological Biomarkers

November 19-20, 2026

44th World Cancer Conference

Dubai, UAE
November 23-24, 2026

8th International Conference on Women Oncology

Miami, USA
November 23-24, 2026

7th Cancer Diagnostics & Treatment Conference

Miami, USA
November 24-25, 2026

6th International Conference on Oncology and Cancer

Paris, France
December 03-04, 2026

10th Global Meeting on Oncology and Radiology

Madrid, Spain
December 08-09, 2026

14th Euro Breast Cancer and Therapeutics

Paris, France
December 08-09, 2026

27th World Congress on Cancer Summit

Paris, France
February 15-16, 2027

5th World Congress on Oral Cancer

Singapore City, Singapore
April 15-16, 2027

12th World Conference on Breast and Cervical Cancer

Amsterdam, Netherlands
April 26-27, 2027

26th World Congress on Cancer and Diagnostics

Barcelona, Spain
April 27-28, 2027

37th Experts Meet On Cancer Research & Therapy

Paris, France
May 05-06, 2027

7th World Congress on Breast Cancer

Berlin, Germany
May 05-06, 2027

23rd International Conference on Cancer Research

Berlin, Germany

Cytological Biomarkers Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in